Proactive Investors - Run By Investors For Investors

Sativa Investments completes 1000th cannabinoid and terpenes test at PhytoVista facility

Cannabinoids are a class of around 113 compounds found in cannabis plants, while terpenes are essential oils that can often enhance their effects
Cannabis testing
The lab is aiming to test medicinal cannabis once it has a handling licence from the Home Office

Sativa Investments PLC (LON:SATI) has completed its 1000th test of cannabinoid and terpenes at its on-site PhytoVista testing laboratory.

Cannabinoids are a class of around 113 compounds found in cannabis plants and include its medicinal component cannabidiol (CBD) and the psychoactive chemical tetrahydrocannabinol (THC).

READ: Sativa Investments brings inexpert to aid its move into the CBD veterinary market

Terpenes are essential oils extracted from the cannabis plant that can enhance the effects of its various cannabinoids, with most of them also carrying anti-pain or anti-inflammatory benefits.

The cannabis investment firm said increased growth of the CBD industry in the UK had led to a rise in demand for testing and batch certifications, of which PhytoVista is a leading service provider.

The laboratory is designed to test and certify that products and samples conform to regulation and is believed to be the only CBD-focused facility in the UK. Sativa said the lab is aiming to test medicinal cannabis products once it has a handling licence granted by the Home Office.

The company added that it had recruited an analytical chemist and a microbiologist at the lab to help expand capacity while its chief scientific officer, Nick Clarkson, was developing new testing methods while the firm sought accreditation of ISO 17025, which regulates the competency of laboratories.

PhytoVista already operates with an ISO 17025 accreditation.

Geremy Thomas, founder and chief executive of Sativa, said the 1000th test was “an early milestone” in the company’s “holistic seed-to-consumer strategy”, with PhytoVista "a key part of Sativa's internal strategic development as having an in-house, on-site testing facility is assisting the Company's Home Office Research Licence application”.

“The laboratory is also attracting significant interest from the pharmaceutical and academic research areas which need an independent testing facility that mandates Good Laboratory Practice to verify and validate their own findings", he added.

The company's shares, which are traded on the NEX exchange, were at 5.9p in late-morning on Thursday.

--Adds share price--

View full SATI profile View Profile

Sativa Investments Timeline

Related Articles

pills
April 12 2019
The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use
Scientist
December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq
Sativa
April 02 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has made significant progress since it started trading on NEX.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use